Your browser is no longer supported. Please, upgrade your browser.
IDRA Idera Pharmaceuticals, Inc. monthly Stock Chart
IDRA [NASD]
Idera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.83 Insider Own0.40% Shs Outstand32.81M Perf Week-10.32%
Market Cap230.98M Forward P/E- EPS next Y-2.75 Insider Trans-97.40% Shs Float21.69M Perf Month-15.38%
Income-65.60M PEG- EPS next Q-0.58 Inst Own40.20% Short Float2.36% Perf Quarter0.96%
Sales0.80M P/S288.73 EPS this Y-39.30% Inst Trans1.14% Short Ratio1.05 Perf Half Y-43.59%
Book/sh3.14 P/B2.24 EPS next Y-5.00% ROA-65.50% Target Price18.33 Perf Year-63.18%
Cash/sh- P/C- EPS next 5Y- ROE-74.20% 52W Range5.20 - 20.40 Perf YTD-58.29%
Dividend- P/FCF- EPS past 5Y12.40% ROI-61.60% 52W High-65.49% Beta2.37
Dividend %- Quick Ratio7.00 Sales past 5Y77.60% Gross Margin- 52W Low35.38% ATR0.76
Employees62 Current Ratio7.00 Sales Q/Q0.00% Oper. Margin- RSI (14)35.94 Volatility11.79% 9.68%
OptionableYes Debt/Eq0.00 EPS Q/Q48.60% Profit Margin- Rel Volume1.02 Prev Close8.50
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume488.75K Price7.04
Recom1.70 SMA20-19.09% SMA50-20.08% SMA200-43.20% Volume494,024 Change-17.18%
Sep-24-18Initiated Barclays Overweight $14
Aug-15-18Resumed JP Morgan Overweight $15
Nov-09-17Initiated H.C. Wainwright Buy $4
Apr-25-17Initiated Robert W. Baird Outperform $5
Mar-22-17Initiated JMP Securities Mkt Outperform
Feb-01-17Reiterated Wedbush Outperform $6
Jan-06-16Initiated Wedbush Outperform $6
Jun-15-15Initiated JP Morgan Overweight
Mar-03-14Initiated Cowen Outperform
Mar-24-10Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $10
Nov-21-08Initiated Noble Financial Buy
Oct-27-08Upgrade Susquehanna Financial Negative → Neutral
Aug-06-08Downgrade Canaccord Adams Buy → Hold
May-07-08Downgrade Janney Mntgmy Scott Buy → Neutral
May-02-08Downgrade Susquehanna Financial Neutral → Negative $11
Oct-19-18 06:00AM  Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment at the 2018 European Society for Medical Oncology (ESMO) Congress GlobeNewswire -17.18%
Oct-15-18 07:55AM  Report: Developing Opportunities within Callon Petroleum, National Oilwell Varco, GameStop, Papa John's International, Baker Hughes, a GE company, and Idera Pharmaceuticals Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-11-18 08:34AM  vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session Zacks -5.75%
Sep-25-18 03:47PM  What does Idera Pharmaceuticals Incs (NASDAQ:IDRA) Balance Sheet Tell Us About Its Future? Simply Wall St.
Sep-18-18 04:01PM  Idera Pharmaceuticals Announces Appointment of Howard Pien to its Board of Directors GlobeNewswire
Sep-11-18 07:00AM  Idera Pharmaceuticals Announces Corporate Organizational Changes GlobeNewswire
Aug-30-18 07:30AM  Idera Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-18-18 08:32AM  These 3 Stocks Crushed It This Week: Are They Buys Now? Motley Fool
Aug-14-18 07:35AM  Research Report Identifies Acushnet, Capitol Federal Financial, Laredo Petroleum, Intrexon, Corning, and Idera Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +15.16%
Aug-12-18 11:46AM  3 Beaten-Down Biotech Stocks: Can They Recover? Motley Fool
Aug-10-18 08:00AM  Todays Research Reports on Stocks to Watch: Portola Pharmaceuticals and Idera Pharmaceuticals ACCESSWIRE -14.50%
Aug-09-18 07:00AM  Idera Pharmaceuticals To Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire +26.91%
Aug-07-18 03:38PM  BioCryst banks gross proceeds of $57.5M from offering American City Business Journals
Aug-06-18 02:18PM  BioCryst gets FDA nod on key drug American City Business Journals
Aug-02-18 06:05PM  Idera Pharmaceuticals (IDRA) Reports Q2 Loss, Lags Revenue Estimates Zacks +5.44%
04:57PM  Idera: 2Q Earnings Snapshot Associated Press
04:30PM  Idera Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
02:40PM  Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today Motley Fool
Jul-27-18 11:58AM  Idera Pharmaceuticals Announces One-for-Eight Reverse Stock Split GlobeNewswire -6.33%
Jul-17-18 08:37AM  Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4 Benzinga
Jul-16-18 07:00AM  Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook GlobeNewswire
Jul-12-18 08:37AM  Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial Benzinga
Jul-11-18 05:33PM  Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today Motley Fool -20.44%
02:34PM  Why Idera Pharmaceuticals Is Sinking Today Motley Fool
01:26PM  Spurned at the altar: BioCryst shareholders reject merger with Exton's Idera Pharmaceuticals American City Business Journals
11:56AM  Future of Idera's Cambridge office uncertain after failed merger American City Business Journals
09:41AM  Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More Zacks
08:15AM  Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares Benzinga
Jul-10-18 06:00PM  No deal: BioCryst shareholders thwart merger with Idera American City Business Journals
05:36PM  [$$] Idera Pharmaceuticals and BioCryst Pharmaceuticals Terminate Merger Plans The Wall Street Journal
04:35PM  BioCryst's stock jumps, Idera drops as proposed merger called off MarketWatch
04:01PM  Idera Pharmaceuticals Announces Termination of Merger Agreement with BioCryst Pharmaceuticals GlobeNewswire
Jun-27-18 07:20AM  Free Technical Research on Nektar Therapeutics and Three More Biotech Equities ACCESSWIRE
Jun-23-18 12:01AM  [$$] Barington Capital Nudges Xerium Technologies Barrons.com
Jun-20-18 04:20PM  Great Point Partners, LLC Remains Opposed To The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. PR Newswire
Jun-14-18 07:09AM  Wired News - Idera Pharma Announced Phase-2 Trial Results of IMO-8400 in Adult Patients with Dermatomyositis ACCESSWIRE
Jun-13-18 10:28AM  Idera Stock Down, Study on Dermatomyositis Candidate Fails Zacks
07:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-12-18 07:42AM  Idera Pharmaceuticals' stock plummets after phase 2 trial failure of dermatomyositis treatment MarketWatch -8.81%
07:30AM  Idera Pharmaceuticals Reports Results from Phase 2 Trial of IMO-8400 in Dermatomyositis GlobeNewswire
Jun-04-18 02:05PM  Here's Why Idera Pharmaceuticals Fell as Much as 15.4% Today Motley Fool
07:30AM  Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-24-18 07:15AM  Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks ACCESSWIRE
06:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-18-18 09:59AM  Options Traders Expect Huge Moves in Idera Pharmaceuticals (IDRA) Stock Zacks
May-17-18 07:55PM  Should You Be Concerned With Idera Pharmaceuticals Incs (NASDAQ:IDRA) -74.83% Earnings Drop? Simply Wall St.
May-16-18 07:55AM  New Research Coverage Highlights Tyson Foods, Windstream, Laredo Petroleum, Idera Pharmaceuticals, Diamondrock Hospitality, and Organovo Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
May-09-18 07:09AM  Idera: 1Q Earnings Snapshot Associated Press +7.50%
07:00AM  Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-02-18 08:24AM  BioCryst lands European approval for flu treatment American City Business Journals
Apr-26-18 07:00AM  Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development Program at the American Society of Clinical Oncology (ASCO) Meeting GlobeNewswire
Apr-18-18 07:00AM  Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners Foundation ACCESSWIRE
Apr-17-18 07:00AM  Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting GlobeNewswire
Apr-16-18 07:00AM  Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory Melanoma GlobeNewswire -5.35%
Apr-10-18 02:51PM  Vote on proposed merger of biopharm firms pushed back American City Business Journals
07:30AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger Business Wire
Apr-06-18 04:07PM  [$$] Activist Starboard Value Looks Into Forest City Realty Barrons.com
Apr-03-18 02:38PM  Why another BioCryst shareholder plans to vote against Idera merger American City Business Journals +5.56%
Apr-02-18 08:13AM  RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals PR Newswire -11.96%
08:00AM  Idera Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with BioCryst Pharmaceuticals GlobeNewswire
Mar-29-18 08:20AM  Todays Research Reports on Trending Tickers: Idera Pharmaceuticals and Incyte ACCESSWIRE
Mar-22-18 12:00PM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-14-18 02:58PM  Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now Insider Monkey
Mar-07-18 07:54AM  Idera reports 4Q loss Associated Press
07:30AM  Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update GlobeNewswire
Mar-01-18 07:00AM  Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301) GlobeNewswire
Feb-27-18 08:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger GlobeNewswire
Feb-26-18 08:45AM  BioCryst, Idera outline specifics on merger value American City Business Journals
Feb-19-18 02:24PM  Lifshitz & Miller LLP Announces Investigation of Advance Auto Parts, Inc., Ballard Power Systems, Inc., Connecture, Inc., Idera Pharmaceuticals, Inc., Impinj Inc., Obalon Therapeutics, Inc., and Super Micro Computer, Inc. PR Newswire
01:00PM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences GlobeNewswire
Feb-02-18 08:15AM  Investor Expectations to Drive Momentum within Hurco Companies, L.B. Foster, Upland Software, Idera Pharmaceuticals, United Parcel Service, and Geron Discovering Underlying Factors of Influence GlobeNewswire
Jan-30-18 11:25AM  RM LAW Announces Investigation of Idera Pharmaceuticals, Inc. PR Newswire
Jan-24-18 01:44PM  IDERA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger Business Wire -8.33%
Jan-23-18 09:26AM  BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall Zacks
06:35AM  Cambridge's Idera plans eventual move out of state after merger with BioCryst American City Business Journals
Jan-22-18 04:44PM  Why II-VI, Sanmina, and Idera Pharmaceuticals Slumped Today Motley Fool -14.90%
04:05PM  BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love Motley Fool
03:52PM  SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Idera Pharmaceuticals, Inc. - IDRA PR Newswire
02:20PM  Durham's BioCryst merging with Idera, moving some ops out of state American City Business Journals
01:20PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Idera Pharmaceuticals, Inc. (IDRA) on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
10:43AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Idera Pharmaceuticals, Inc. to BioCryst Pharmaceuticals, Inc. is Fair to Shareholders Business Wire
08:41AM  BioCryst and Idera to merge into rare disease company MarketWatch
08:30AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases GlobeNewswire
Jan-11-18 03:18PM  7 High-Risk, High-Reward Stocks to Buy Now InvestorPlace
Jan-05-18 07:00AM  Idera Pharmaceuticals Provides 2018 Update and Outlook GlobeNewswire
Jan-03-18 02:38PM  Where Idera Pharmaceuticals Inc (NASDAQ:IDRA) Stands In Terms Of Earnings Growth Against Its Industry Simply Wall St.
Dec-26-17 12:57PM  Idera Pharmaceuticals, Inc. Value Analysis (NASDAQ:IDRA) : December 26, 2017 Capital Cube
Dec-22-17 07:18AM  Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : December 22, 2017 Capital Cube
Dec-20-17 11:47AM  ETFs with exposure to Idera Pharmaceuticals, Inc. : December 20, 2017 Capital Cube
Dec-08-17 01:03PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : December 8, 2017 Capital Cube
Dec-04-17 07:04AM  3 Top Stocks Under $5 Motley Fool
Dec-01-17 07:20AM  Wired News Idera Pharma Gets Fast Track Designation for IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma ACCESSWIRE
Nov-29-17 07:30AM  U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma GlobeNewswire
Nov-28-17 08:00AM  Analysis: Positioning to Benefit within Kirby, AmerisourceBergen, Celgene, Sabre, Noble Energy, and Idera Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-27-17 04:01PM  Idera to Present at the 29th Annual Piper Jaffray Healthcare Conference GlobeNewswire
02:13PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : November 27, 2017 Capital Cube
Nov-21-17 07:33AM  Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : November 21, 2017 Capital Cube
Nov-17-17 12:07PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : November 17, 2017 Capital Cube
Nov-10-17 08:37AM  Is the Options Market Predicting a Spike in Idera (IDRA) Stock? Zacks
Nov-09-17 01:12PM  Why Idera Pharmaceuticals Inc. Jumped Higher Today Motley Fool +14.12%
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Exton, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pillar Invest Corp10% OwnerAug 09Sale6.3055,000346,4430Aug 17 05:44 PM
Pillar Invest Corp10% OwnerAug 08Sale5.9178,107461,4490Aug 17 05:44 PM
MILANO VINCENTPresident & CEOAug 07Buy5.5110,00055,10040,816Aug 08 07:35 PM
GERAGHTY JAMES ADirectorAug 07Buy5.5810,00055,80065,433Aug 08 07:35 PM
Pillar Invest Corp10% OwnerAug 07Sale5.58166,893931,8160Aug 17 05:44 PM
Pillar Invest Corp10% OwnerJul 20Sale0.86492,567422,6720Jul 24 05:52 PM
Pillar Invest Corp10% OwnerJul 19Sale0.88556,000489,5020Jul 24 05:52 PM
Pillar Invest Corp10% OwnerJul 18Sale0.851,725,0001,470,3900Jul 24 05:52 PM
Pillar Invest Corp10% OwnerJul 17Sale0.99874,505862,5240Jul 19 06:13 PM
Pillar Invest Corp10% OwnerJul 16Sale1.01735,771743,6440Jul 19 06:13 PM
Pillar Invest Corp10% OwnerJul 13Sale1.05250,500264,0520Jul 19 06:13 PM
BAKER BROS. ADVISORS LPDirectorMar 15Option Exercise0.4720,316,3279,548,67434,193,251Mar 15 04:10 PM
Pillar Invest Corp10% OwnerJan 17Sale2.40200,000480,0000Jan 19 04:51 PM
Pillar Invest Corp10% OwnerDec 15Sale1.9133,83064,5270Dec 15 05:50 PM
Pillar Invest Corp10% OwnerDec 14Sale2.001,166,1702,332,6010Dec 15 05:50 PM
Pillar Invest Corp10% OwnerDec 13Sale1.931,100,0002,118,1700Dec 15 05:50 PM
BAKER BROS. ADVISORS LPDirectorOct 26Buy1.508,000,00012,000,00016,557,473Oct 30 05:12 PM